Completed PHASE2 INTERVENTIONAL NCT00004197

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma

Interventions cyclophosphamide doxorubicin hydrochloride keyhole limpet hemocyanin mitoxantrone hydrochloride prednisone sargramostim tumor cell-based vaccine therapy vincristine sulfate

Updated 6 times since 2017 Last updated: Sep 3, 2023 Started: Jun 25, 1999 Primary completion: Jan 1, 2002 Completion: Nov 20, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Nebraska

Data source: University of Nebraska

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Omaha, United States
• Stanford, United States